Arachidonoyl Ethanolamide Phosphate – 5 mg

Brand:
Cayman
CAS:
183323-26-4
Storage:
-20
UN-No:
Excepted Quantity - 1170 / 3

Arachidonoyl ethanolamide (AEA; Item No. 90050) was the first endogenous cannabinoid (CB) to be isolated and characterized as an agonist acting on the same receptors (CB1 and CB2) as Δ9-THC (Item No. 12068).{1134,2713} Since that time, a number of related endocannabinoids have been isolated, most notably 2-arachidonoyl glycerol (2-AG; Item No. 62160).{2713} The phosphate ester of AEA, AEA-P, has been tested as a water soluble prodrug version of AEA in the treatment of C6 glioma cells in vivo. Here it acts with essentially the same potency as AEA.{11520} However, when tested for inhibition of AEA binding to isolated rat brain CB1 receptors, AEA-P is about 5-fold less potent as an agonist with a Ki of about 200 nM.{9580} The phosphate esters of AEA and its analogs are also structural variants of lysophosphatidic acid (LPA). However, the effects of AEA-P on the various LPA receptors have not been tested.  

 

Available on backorder

SKU: 10180 - 5 mg Category:

Description

The phosphate ester (and water-soluble prodrug) of AEA (Item No. 90050); acts with equal potency as AEA in the treatment of C6 glioma cells in vivo; 5-fold less potent than AEA as an agonist of isolated rat brain CB1 receptors (Ki = 200 nM); also a structural variant of LPA


Formal name: N-(2-(phosphonooxy)ethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide

Synonyms:  AEA-P|Anandamide Phosphate

Molecular weight: 427.5

CAS: 183323-26-4

Purity: ≥98%

Formulation: A solution in ethanol


Product Type|Biochemicals|Lipids|Fatty Amides||Research Area|Lipid Biochemistry|Endocannabinoid/Endocannabinoid-like||Research Area|Neuroscience|Cannabinoid Research|CB1 & CB2 Receptors||Research Area|Neuroscience|Cannabinoid Research|Endocannabinoids